Issue 23, 2021

A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy

Abstract

Triple-negative breast cancer (TNBC) is associated with a worse prognosis and higher mortality than other breast cancers, and intensive effort has been made to develop therapies targeting TNBC. TNBC shows higher expression levels of programmed cell death ligand 1 (PD-L1) than other breast cancer types, which leads to a decrease in the killing effects of CD8+ T cells in the tumor microenvironment. Inhibitors of apoptosis proteins (IAPs) could prevent cell death through suppressing caspase activity. Here, Birinapant, an antagonist of IAPs, was found to promote the tumor infiltration of CD8+ T cells via increasing the secretion of the chemokine CXCL9. In addition, Birinapant could inhibit tumor growth via increasing the secretion of and the sensitivity to TNF-α in a TNBC xenotransplantation mouse model. Consequently, liposomes encapsulating Birinapant and siPD-L1 mediated a form of combination therapy based on two drugs to significantly increase the therapeutic effects toward TNBC.

Graphical abstract: A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy

Article information

Article type
Paper
Submitted
17 Aug 2021
Accepted
06 Oct 2021
First published
13 Oct 2021

Biomater. Sci., 2021,9, 8007-8018

A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy

T. Gong, Y. Cai, F. Sun, J. Chen, Z. Su, X. Shuai and H. Shan, Biomater. Sci., 2021, 9, 8007 DOI: 10.1039/D1BM01299A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements